Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Lotte Biologics is allocating fresh investments in its own home ground to build three new production plants. The leading pharma company is spending $3 billion for the new facilities that will be constructed in South Korea.
Lotte Biologics is aiming to complete the new factories by the year 2030, and the plan is to build a bio-industrial complex where it will house the three plants. The company is expecting a production capacity of 360,000 liters of anti-body medicines per year in Korea.
As per Pulse News, Lotte Biologic’s chief executive officer, Lee Won Jik, revealed the company’s mid and long-term plan when he attended the J.P. Morgan Healthcare Conference in San Francisco. At that time, he said that they would bolster their business competitiveness to become a major competitor in the contract development and manufacturing organization (CDMO) market. The company’s strategy to achieve this is to acquire assets and build new facilities.
To set its plan in motion, the firm will start the construction of its first plant in the Lotte Bio Campus production complex within the second half of this year. This first factory is set to operate for commercial production by 2027. As for the entire complex, it is expected to be completed in 2034.
Lotte Biologics planned this new investment after completing its acquisition of Bristol Myers Squibb’s manufacturing plant in Syracuse, New York. It purchased the facility for $160 million earlier this month as part of its strategy to expand overseas.
“Each plant will require approximately $1 billion in investment for a total of $3 billion invested by 2030,” Lee said during the presentation. The three plants will each have a 120,000-liter capacity, for a combined 360,000 liters.” Korea Joongang Daily quoted Lotte Biologics’ CEO as saying during the conference with regards to its latest investment in South Korea.
He added, “While the locations have not been announced, the bio company plans to start the construction of the first plant in the second half of this year. The first plant is set to start commercial manufacturing in 2027 after completing the facility in the second half of 2025. It aims to run all of three factories by 2034 and generate $3 billion in sales annually with a profit margin of 35 percent.”
